Sr One Capital Management, Llc bought $38.0M of Zenas BioPharma (ZBIO)
Executed Sep 16 2024, disclosed Sep 16 2024, the same day.
Over the 21 trading sessions from the disclosed entry session (Sep 16 2024), the stock returned +4.9% (delay-adjusted); from the execution session (Sep 16 2024), +4.9%. Derived: entry at the session's open, exit at the close 20 sessions later.
Sr One Capital Management, Llc (10% owner) filed 3 Form 4 reports as a reporting entity in the trailing twelve months (3 purchases, 0 sales), most often in AVLN. Across 3 priced purchase filings, the average 21-session return was +7.4% from execution and +11.3% from disclosure (delay-adjusted; derived). The largest single filing was $10.0M of ODTX (555,555 sh across 3 lots, as filed), executed May 11.
Healthcare · Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-ba…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→126,315 sh across 2 lots
Exec Oct 9 2025
Filed Oct 14 2025 · 5:14 PM ET